Skip to main content
. 2016 Sep;101(9):1102–1109. doi: 10.3324/haematol.2016.147041

Figure 4.

Figure 4.

Overall survival by regimen type and immunoparesis status at first-line treatment. ARD: average relative difference. A. Autologous stem cell transplantation (ASCT) B. Melphalan-based regimen C. Bortezomib-based regimen D. IMiD-based regimen.